Indication:

Tenofovir Alafenamide is indicated for the management of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Pharmacology:

Tafecta, containing Tenofovir Alafenamide as its active component, functions as an oral nucleoside reverse transcriptase inhibitor (NRTI) designed to combat the hepatitis B virus (HBV). Upon ingestion, Tenofovir Alafenamide undergoes metabolic transformation into tenofovir, the drug’s active form.

Tenofovir diphosphate, which is the phosphorylated state of tenofovir, disrupts HBV replication by competing with deoxyadenosine 5′-triphosphate for incorporation into viral DNA via the HBV polymerase. This competitive mechanism halts the formation of viral DNA chains, effectively impeding HBV replication.

pre-Initiation :

Before initiating Tenofovir Alafenamide treatment, patients should undergo screening for HIV-1 infection. However, Tenofovir Alafenamide should not be used alone in patients with HIV infection. Additionally, it is advisable to assess various parameters including serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose, and urine protein before starting Tenofovir Alafenamide, with periodic monitoring during therapy as clinically warranted.

Interactions: Details regarding potential drug interactions.

 Dosage and Administration:

Adults should take Tenofovir Alafenamide orally at a dose of 25 mg (one tablet) once daily, preferably with food.No dose adjustments for Tenofovir Alafenamide are required in patients with mild, moderate, or severe renal impairment. However, the medication is not recommended for individuals with end-stage renal disease (estimated creatinine clearance below 15 mL per minute).No modifications to the Tenofovir Alafenamide dosage are necessary in patients with mild hepatic impairment (Child-Pugh A). However, the drug is not recommended for use in individuals with decompensated hepatic impairment (Child-Pugh B or C).

Side Effects:

Comprehensive information on observed adverse effects.
Precautions and Warnings:

Guidance on cautious use and associated risks.

Overdose Effects

Information on the effects and management of Tenofovir Alafenamide overdose.